Articles in 2007

Working with patient advocacy groups poses many challenges to entrepreneurs, but the benefits can be substantial. Here, we examine the relationship between biotech PTC Therapeutics and Parent Project Muscular Dystrophy to highlight some key factors for success in such partnerships.

There's a lot to consider before out-licensing patent rights. Here, a law student and a seasoned patent attorney outline what every bioentrepreneur should know before tackling the task.

Many cities and countries still view the foundation of a biotech sector as desirable for a high-tech, intellectually driven economy. But a discussion by seasoned biotech management and investors suggests that attaining an environment with the right mix of money, management and innovation remains a difficult and long-term challenge.

A veteran of the tech transfer business offers guidance on how to manage interuniversity research—and how to avoid the wrangling over IP that often accompanies invention.

Pharma has pipelines to fill and cash to spend. But just what types of partners and products is it looking for?

Many biotech products experience setbacks and disappointments along the path to commercial success. Here, three industry insiders provide some suggestions for the best practice when a product is returned or discontinued by a licensee.

A serial entrepreneur provides his insights into the pitfalls you may face when seeking financing for your company and some key strategies to avoid them.

Two of KPMG in the UK's tax consultants summarize basic tax principles to bear in mind when starting a life science venture.

Charitable foundations are increasingly looking to help promising drugs reach the market. Often the advice and networking opportunities they provide are as valuable as the funding.

For most biotech companies, the US market represents their best avenue to financial success. For non-US companies, that might mean opening a subsidiary, and that's a move that requires careful planning.

Europe has a substantial big pharma presence and a continuing tradition of scientific excellence, but several factors still hinder the development of a vibrant biotech sector.